((自动化翻译由路透提供，请见免责声明 ))
11月29日 - ** 生物技术公司Voyager Therapeutics的 股价盘前上涨6.9%至6.18美元。
** Wedbush分析师Yun Zhong以 "跑赢大盘 "的评级和11美元的预测价格开始了 对该公司股票的投资；此前Wedbush分析师对该公司股票的评级为 "中性"，预测价格为7美元。
** 新的预测值较该股上次收盘价上涨了 90.3
** 券商称，VYGR针对神经退行性疾病（包括阿尔茨海默氏症和渐冻症）的项目获得的积极数据增强了他们的信心。
** Wedbush 称，尽管早期治疗的风险很高，但该公司股价处于低位，创造了一个 "有吸引力的投资机会
** 所有十家券商都将该股评为 "买入 "或更高评级；他们的 PT 中值为 18 美元 - LSEG
** 截至上次收盘，该股今年累计下跌31.5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.